There's been a flurry of activities around Viatris (VTRS) recently, with options traders potentially signaling information not in public domain. The company announced early tender results and increased a maximum tender offer. Its second quarter financial results for 2024 were revealed, along with an outpacing of earnings estimates, though sales fell short. A 2023 sustainability report emphasized workforce health and safety, and the company wrapped up cash tender offers. Its pricing terms for pending cash tender offers were also laid out.
Second quarter earnings surpassed estimates and the third quarter results are set to be reported on November 7, 2024. After its Q1 sales and earnings lagged behind estimates, the stock fell. Note-worthy mid-year milestones included the appointment of Rogerio Vivaldi Coelho, M.D., to the Board of Directors and its participation in the Goldman Sachs annual Global Healthcare Conference. The stock dipped by 3.5% since its last earnings report but was named one of TIME’s most sustainable companies in 2024. Legal troubles arose as Novartis and Viatris faced lawsuits over 'HeLa' cell misuse claims. However, growth and dividends remain promising, despite mixed Q2 results. The company sees a revenue growth of approximate 2% for 2024 on a divestiture-adjusted operational basis.
Viatris VTRS News Analytics from Sun, 01 Oct 2023 07:00:00 GMT to Fri, 20 Sep 2024 21:51:52 GMT - Rating 5 - Innovation 2 - Rumor 0
